Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients

Molecular and Cellular Endocrinology

Volumn 355, Issue 1, 2012, Pages 162-168

  Williams, Tracy Ann ^a   Monticone, Silvia ^a   Urbanet, Riccardo ^b   Bertello, Chiara ^a   Giraudo, Giuseppe ^a   Vettor, Roberto ^b   Fallo, Francesco ^b   Veglio, Franco ^a   Mulatero, Paolo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Aldosterone; Aldosterone producing adenomas; Primary aldosteronism; Secondary hypertension

Indexed keywords

ALDOSTERONE; EPLERENONE; MESSENGER RNA; POTASSIUM;

ADIPOCYTE; ADIPONECTIN GENE; ADULT; AGE DISTRIBUTION; ALDOSTERONE BLOOD LEVEL; ARTICLE; BODY MASS; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSOLIC PHOSPHOENOLPYRUVATE CARBOXYKINASE 1 GENE; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID METABOLISM; MALE; MOLECULAR PATHOLOGY; PERILIPIN GENE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA GENE; POTASSIUM BLOOD LEVEL; PRIMARY CELL CULTURE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SEX DIFFERENCE;

ADIPOCYTES; ADIPONECTIN; ADULT; AGED; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; CARRIER PROTEINS; CELLS, CULTURED; DOWN-REGULATION; FEMALE; GENE EXPRESSION; HUMANS; HYPERALDOSTERONISM; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPID METABOLISM; MALE; MIDDLE AGED; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PHOSPHOPROTEINS; POTASSIUM; PPAR GAMMA; SPIRONOLACTONE;

EID: 84858748692     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.02.007     Document Type: Article

References (36)

1. Arimura N., Horiba T., Imagawa M., Shimizu M., Sato R. The peroxisome proliferator-activated receptor gamma regulates expression of the perilipin gene in adipocytes. J. Biol. Chem. 2004, 279:10070-10076.
2. Barzon L., Scaroni C., Sonino N., Fallo F., Paoletta A., Boscaro M. Risk factors and long-term follow-up of adrenal incidentalomas. J. Clin. Endocrinol. Metab. 1999, 84:520-526.
3. Beale E.G., Hammer R.E., Antoine B., Forest C. Disregulated glyceroneogenesis: PCK1 as a candidate diabetes and obesity gene. Trends. Endocrinol. Metab. 2004, 15:129-135.
4. Bochud M., Nussberger J., Bovet P., Maillard M.R., Elston R.C., Paccaud F., Shamlaye C., Burnier M. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006, 48:239-245.
5. Born-Frontsberg, E., Reincke, M., Rump, L.C., Hahner, S., Diederich, S., Lorenz, R., Allolio, B., Seufert, J., Schirpenbach, C., Beuschlein, F., Bidlingmaier, M., Endres, S., Quinkler, M., Participants of the German Conn's Registry, 2009. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J. Clin. Endocrinol. Metab. 94, 1125-1130.
6. Brasaemle D.L. Thematic review series: adipocyte biology. The perilipin family of structural lipid droplet proteins: stabilization of lipid droplets and control of lipolysis. J. Lipid. Res. 2007, 48:2547-2559.
7. Catena C., Lapenna R., Baroselli S., Nadalini E., Colussi G., Novello M., Favret G., Melis A., Cavarape A., Sechi L.A. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J. Clin. Endocrinol. Metab. 2006, 91:3457-3463.
8. Fallo F., Veglio F., Bertello C., Sonino N., Della, Mea P., Ermani M., Rabbia F., Federspil G., Mulatero P. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J. Clin. Endocrinol. Metab. 2006, 91:454-459.
9. Fallo F., Della, Mea P., Sonino N., Bertello C., Ermani M., Vettor R., Veglio F., Mulatero P. Adiponectin and insulin sensitivity in primary aldosteronism. Am. J. Hypertens. 2007, 20:855-861.
10. Garg R., Hurwitz S., Williams G.H., Hopkins P.N., Adler G.K. Aldosterone production and insulin resistance in healthy adults. J. Clin. Endocrinol. Metab. 2010, 95:1986-1990.
11. Giacchetti G., Ronconi V., Turchi F., Agostinelli L., Mantero F., Rilli S., Boscaro M. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J. Hypertens. 2007, 25:177-186.
12. Goldstein B.J., Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J. Clin. Endocrinol. Metab. 2004, 89:2563-2568.
13. Guo C., Ricchiuti V., Lian B.Q., Yao T.M., Coutinho P., Romero J.R., Li J., Williams G.H., Adler G.K. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008, 117:2253-2261.
14. Hannemann A., Meisinger C., Bidlingmaier M., Döring A., Thorand B., Heier M., Belcredi P., Ladwig K.H., Wallaschofski H., Friedrich N., Schipf S., Lüdemann J., Rettig R., Peters J., Volzke H., Seissler J., Beuschlein F., Nauck M., Reincke M. Association of plasma aldosterone with the metabolic syndrome in two German populations. Eur. J. Endocrinol. 2011, 164:751-758.
15. Hirata A., Maeda N., Hiuge A., Hibuse T., Fujita K., Okada T., Kihara S., Funahashi T., Shimomura I. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc. Res. 2009, 84:164-172.
16. Ingelsson E., Pencina M.J., Tofler G.H., Benjamin E.J., Lanier K.J., Jacques P.F., Fox C.S., Meigs J.B., Levy D., Larson M.G., Selhub J., D'Agostino R.B., Wang T.J., Vasan R.S. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham offspring study. Circulation 2007, 116:984-992.
17. Kidambi S., Kotchen J.M., Grim C.E., Raff H., Mao J., Singh R.J., Kotchen T.A. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 2007, 49:704-711.
18. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., Nagaretani H., Matsuda M., Komuro R., Ouchi N., Kuriyama H., Hotta K., Nakamura T., Shimomura I., Matsuzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001, 50:2094-2099.
19. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., Furuyama N., Kondo H., Takahashi M., Arita Y., Komuro R., Ouchi N., Kihara S., Tochino Y., Okutomi K., Horie M., Takeda S., Aoyama T., Funahashi T., Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 2002, 8:731-737.
20. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985, 28:412-419.
21. McGarry J.D. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002, 51:7-18.
22. Milliez P., Girerd X., Plouin P.F., Blacher J., Safar M.E., Mourad J.J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 2005, 45:1243-1248.
23. Mulatero P., Bertello C., Rossato D., Mengozzi G., Milan A., Garrone C., Giraudo G., Passarino G., Garabello D., Verhovez A., Rabbia F., Veglio F. Roles of clinical criteria, computed tomography scan, and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes. J. Clin. Endocrinol. Metab. 2008, 93:1366-1371.
24. Mulatero P., Bertello C., Sukor N., Gordon R., Rossato D., Daunt N., Leggett D., Mengozzi G., Veglio F., Stowasser M. Impact of different diagnostic criteria during adrenal vein sampling on reproducibility of subtype diagnosis in patients with primary aldosteronism. Hypertension 2010, 55:667-673.
25. Mulatero P., Monticone S., Veglio F. Diagnosis and treatment of primary aldosteronism. Rev. Endocr. Metab. Disord. 2011, 12:3-9.
26. Olswang Y., Cohen H., Papo O., Cassuto H., Croniger C.M., Hakimi P., Tilghman S.M., Hanson R.W., Reshef L. A mutation in the peroxisome proliferator-activated receptor gamma-binding site in the gene for the cytosolic form of phosphoenolpyruvate carboxykinase reduces adipose tissue size and fat content in mice. Proc. Natl. Acad. Sci. USA 2002, 99:625-630.
27. Pagano C., Pilon C., Calcagno A., Urbanet R., Rossato M., Milan G., Bianchi K., Rizzuto R., Bernante P., Federspil G., Vettor R. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J. Clin. Endocrinol. Metab. 2007, 92:4810-4819.
28. Reincke, M., Rump, L.C., Quinkler, M., Hahner, S., Diederich, S., Lorenz, R., Seufert, J., Schirpenbach, C., Beuschlein, F., Bidlingmaier, M., Meisinger, C., Holle, R., Endres, S., Participants of German Conn's Registry, 2009. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J. Clin. Endocrinol. Metab. 94, 869-875.
29. Reincke, M., Meisinger, C., Holle, R., Quinkler, M., Hahner, S., Beuschlein, F., Bidlingmaier, M., Seissler, J., Endres, S., Participants of the German Conn's Registry, 2010. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn's Registry. Horm. Metab. Res. 42, 435-439.
30. Rossi, G.P., Bernini, G., Desideri, G., Fabris, B., Ferri, C., Giacchetti, G., Letizia, C., Maccario, M., Mannelli, M., Matterello, M.J., Montemurro, D., Palumbo, G., Rizzoni, D., Rossi, E., Pessina, A.C., Mantero, F., PAPY Study Participants, 2006. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 48, 232-238.
31. Saha P.K., Kojima H., Martinez-Botas J., Sunehag A.L., Chan L. Metabolic adaptations in the absence of perilipin: increased beta-oxidation and decreased hepatic glucose production associated with peripheral insulin resistance but normal glucose tolerance in perilipin-null mice. J. Biol. Chem. 2004, 279:35150-35158.
32. Sowers J.R., Whaley-Connell A., Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann. Intern. Med. 2009, 150:776-783.
33. Tansey J.T., Sztalryd C., Gruia-Gray J., Roush D.L., Zee J.V., Gavrilova O., Reitman M.L., Deng C.X., Li C., Kimmel A.R., Londos C. Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity. Proc. Natl. Acad. Sci. USA 2001, 98:6494-6499.
34. Unger R.H. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends. Endocrinol. Metab. 2003, 14:398-403.
35. Urbanet R., Pilon C., Calcagno A., Peschechera A., Hubert E.L., Giacchetti G., Gomez-Sanchez C., Mulatero P., Toffanin M., Sonino N., Zennaro M.C., Giorgino F., Vettor R., Fallo F. Analysis of insulin sensitivity in adipose tissue of patients with primary aldosteronism. J. Clin. Endocrinol. Metab. 2010, 95:4037-4042.
36. Williams T.A., Monticone S., Morello F., Liew C.C., Mengozzi G., Pilon C., Asioli S., Sapino A., Veglio F., Mulatero P. Teratocarcinoma-derived growth factor-1 is upregulated in aldosterone-producing adenomas and increases aldosterone secretion and inhibits apoptosis in vitro. Hypertension. 2010, 55:1468-1475.